FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| CLV | $0.56 |
|
$0.60 | $0.34 | 13.9 |
$0.68 |
|
| EBO | $27.65 |
|
$38.23 | $27.65 | 19.1 |
$34.873 |
|
| EXL | $0.02 | 0.00% | $0.05 | $0.00 |
|
||
| MCP | $0.27 |
|
$0.43 | $0.21 |
|
||
| SIG | $3.04 |
|
$3.32 | $1.26 | 48.9 |
$3.057 |
|
-1.77% 
22.5% Previous Stories
Generic Margins Remain The Issue For Sigma
Sep 15 2009
Brokers were generally nonplussed by the Sigma Pharmaceuticals interim result as margins in the generic business remain a concern and an impediment to group earnings growth.
Stockbrokers Cannot Get Excited About Sigma
Sep 08 2009
Sigma Pharmaceuticals has acquired 15 brands plus a manufacturing facility from BMS and announced a rights issue.
Playing The Lipstick Indicator
Oct 31 2008
Why might Australian Pharmaceutical rejoice in the Lipstick Indicator, and what might this have to do with Downer EDI?
Sigma Struggling With FY Forecasts
Sep 23 2008
Sigma Pharmaceuticals’ first half profit was lower than expected, leading brokers to predict the company will do it tough in meeting its full year targets.
Sigma Is A Value Trap, Brokers Say
Mar 26 2008
While shares in Sigma Pharmaceuticals appear cheap brokers are yet to get excited as earnings risk remains to the downside and there is little evidence the group’s bundling strategy is working.
Southern Cross Equities Positive On API
Jan 17 2008
Australian Pharmaceutical Industries is not exactly flavour of the month for investors but as with Deutsche Bank last month Southern Cross Equities sees value in the stock at current levels.
Latest News
| 1 |
The Market In Numbers – 6 Sep 20259:09 AM - Australia |
| 2 |
ASX Winners And Losers Of Today – 05-09-25Sep 05 2025 - Daily Market Reports |
| 3 |
FNArena Corporate Results Monitor – 05-09-2025Sep 05 2025 - Australia |
| 4 |
Next Week At A Glance – 8-12 Sep 2025Sep 05 2025 - Weekly Reports |
| 5 |
In Case You Missed It – BC Extra Upgrades & Downgrades – 05-09-25Sep 05 2025 - Weekly Reports |